Published in Gene Therapy Weekly, January 18th, 2001
C. Shults and colleagues working at the Veterans Affairs Medical Center in La Jolla, California, pursued their thought "that fibroblasts, which had been genetically engineered to produce fibroblast growth factor-2 (FGF-2), can protect nigrostriatal dopaminergic neurons" by conducting a study in rats. They researchers compared the protective effects of fibroblasts engineered to produce FGF-2 and the enzyme beta-galactosidase (beta-gal) ("Fibroblast growth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.